Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.

Hui, Huang; Jin, Jie; Li, Xin

doi:10.12669/pjms.306.6408

“…Adjuvant BCG therapy, history of previous carcinoma not invading bladder muscle and non-trigonal tumor location were significantly associated with prolonged recurrence-free survival in a study by Segal et al [15]. Tumors that were located in the bladder neck/trigone showed worse cancer-specific survival in a study by Huang et al [16]. In our multivariable analysis, it was shown that the BCG-instillation therapy was an independent factor that influenced overall survival and cancer-specific mortality.…”

Section: Discussionmentioning

confidence: 99%

Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer

Froehner¹,

Ollig²,

Koch³

et al. 2016

View full text Add to dashboard Cite

Purpose: To evaluate the impact of adjuvant intravesical bacillus Calmette-Guérin (BCG) treatment in patients with high-grade transitional cell carcinoma of bladder. Patients and Methods: A total of 207 consecutive patients who underwent transurethral resection for high-grade T1 transitional cell carcinoma of bladder at our institution between January 1, 2005 and December 31, 2012. Of those patients, 77 underwent early cystectomy without BCG instillation and were excluded from the analysis. The overall survival and cancer-specific mortality were compared in 2 different therapy options groups (group of patients who received adjuvant BCG instillation vs. the group of patients who did not receive BCG therapy). Overall mortality was estimated by the Kaplan-Meier method, univariate comparisons were made with the log rank test. The cumulative incidence of deaths from bladder cancer (BC) was determined by univariate and multivariate competing risk analysis. Cox proportional hazard models for competing risks were used to study the combined effects of the variables on BC-specific mortality. Results: The 5-year overall survival in patients with BCG instillation vs. patients who did not receive BCG therapy was 74 vs. 28% (p = 0.0016). In the univariate analysis, the adjuvant intravesical BCG treatment was associated with decreased cancer-specific mortality (p = 0.0062). In the multivariable analysis, the age and the BCG instillation were independent factors of overall survival (hazard ratio 0.26, 95% CI 0.15-0.46, p < 0.0001) and cancer-specific mortality (hazard ratio 0.29, 95% CI 0.12-0.71, p = 0.0067). Conclusion: Dispensing from adjuvant intravesical BCG treatment is associated with increased overall- and disease-specific mortality in patients with T1 high-grade transitional cell carcinoma of bladder. This observation confirms that adjuvant BCG instillation is a crucial part of treatment in this patient population.

show abstract

“…In the past, surgery, radiation and chemotherapy were at the forefront of recommended and accepted treatments for different cancer types. However, the efficacy of these therapies were limited due to (a) high recurrence rate [1,2,3] , (b) hard-to-detect residual metastasis [4,5] , (c) frequent late stage diagnosis [6,7] , (d) elevated refractory cases from resistant cancers [8,9] and (e) invasiveness and toxicity to patients. In response to addressing these drawbacks, a new method entered the treatment groupimmunotherapy.…”

Section: Introductionmentioning

confidence: 99%

CAR-T Therapy for Solid Tumors: Development of New Strategies

Santos¹,

Bernal

²

2020

Trends Immunother

0

View full text Add to dashboard Cite

The recent approval of two CAR-T therapies by US Food and Drug Administration (FDA) marks a very significant development in cell-based cancer immunotherapy. This milestone was demonstrated by the effectiveness of eradicating hematologic cancers using CD19-specific CARs. The success spurred development of immune cell therapies for other cancers, especially solid tumors. The generation of novel CAR constructs for these cancer types represents a major challenge in bringing the technology ‘from-bench-to-bedside‘.In this review, we outline some new technologies we have developed to equip CAR-T cells to enhance efficiency while decreasing toxicity of CAR-T therapies in solid tumors.

show abstract

“…In the past, surgery, radiation and chemotherapy were at the forefront of recommended and accepted treatments for different cancer types. However, the efficacy of these therapies were limited due to (a) high recurrence rate [1,2,3] , (b) hard-to-detect residual metastasis [4,5] , (c) frequent late stage diagnosis [6,7] , (d) elevated refractory cases from resistant cancers [8,9] and (e) invasiveness and toxicity to patients. In response to addressing these drawbacks, a new method entered the treatment group -immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

CAR-T Therapy for Solid Tumors: Development of New Strategies

Santos

¹

,

Bernal

²

2019

Trends Immunother

1

0

View full text Add to dashboard Cite

The recent approval of two CAR-T therapies by US Food and Drug Administration (FDA) marks a very significant development in cell-based cancer immunotherapy. This milestone was demonstrated by the effectiveness of eradicating hematologic cancers using CD19-specific CARs. The success spurred development of immune cell therapies for other cancers, especially solid tumors. The generation of novel CAR constructs for these cancer types represents a major challenge in bringing the technology ‘from-bench-to-bedside‘.In this review, we outline some new technologies we have developed to equip CAR-T cells to enhance efficiency while decreasing toxicity of CAR-T therapies in solid tumors.

show abstract

Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.

Cited by 3 publications

References 1 publication

Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer

Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer

CAR-T Therapy for Solid Tumors: Development of New Strategies

CAR-T Therapy for Solid Tumors: Development of New Strategies

Contact Info

Product

Resources

About